Active Humoral Response Reverts Tumorigenicity through Disruption of Key Signaling Pathway

Immune checkpoint inhibitors such as monoclonal antibodies (mAbs) are amongst the most important breakthroughs in cancer therapeutics. However, high cost and short acting time limits its affordability and clinical application. Therefore, an economical and durable alternative is urgently needed. Prev...

Descripción completa

Detalles Bibliográficos
Autores principales: Yong, Tracer, Chang, Ko-Keng, Wang, Yi-Sheng, Ma, Che
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875535/
https://www.ncbi.nlm.nih.gov/pubmed/35214622
http://dx.doi.org/10.3390/vaccines10020163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875535/
https://www.ncbi.nlm.nih.gov/pubmed/35214622
http://dx.doi.org/10.3390/vaccines10020163

Ejemplares similares